Apixaban
Eliquis (apixaban) is a small molecule pharmaceutical. Apixaban was first approved as Eliquis on 2011-05-18. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat arthroplasty, stroke, and venous thromboembolism. The pharmaceutical is active against coagulation factor X. Eliquis's patents are valid until 2031-02-24 (FDA).
| Trade Name | Eliquis |
|---|---|
| Common Name | Apixaban |
| ChEMBL ID | CHEMBL231779 |
| Indication | arthroplasty, pulmonary embolism, stroke, venous thromboembolism, venous thrombosis |
| Drug Class | Antithrombotic: blood coagulation factor XA inhibitors |
